secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2024-09-10T23:59:59+00:00
Accession:  0001104659-24-098371
Event type: leadership
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio appoints Thomas Kassberg as Class I director and Audit Committee member
--------------------------------------------------------------------------------

- Appointment effective September 10, 2024; Kassberg also joins Audit Committee.
- Kassberg currently Chief Business Officer and EVP at Ultragenyx Pharmaceutical.
- Received non-incentive stock options with $90,000 grant date fair value, vesting over three years.
- Cash compensation per non-executive director policy plus indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000110465924098371/0001104659-24-098371-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000110465924098371/tm2423395d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-098371

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer